CPRX News and Press, Catalyst Pharmaceuticals Inc. From 10/16/23

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 202...

2023-10-13 09:59:46 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals...

The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Cata...

CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Pat...

2023-09-08 17:18:18 ET More on Catalyst Pharmaceuticals Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals Historical earnings data for Catalyst Pharmaceuticals Financial information for Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Jour...

2023-08-30 17:36:00 ET Summary Catalyst Pharmaceuticals reported a significant increase in product revenues, with a YoY growth of 87.5% in Q2 2023. The company maintains a strong financial position with $178.8M in cash and cash equivalents and no immediate need for additional fina...

CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare disea...

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseas...

2023-08-10 11:37:06 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Alicia Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer ...

2023-08-09 16:23:21 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.53 beats by $0.24 . Revenue of $99.58M (+87.5% Y/Y) beats by $7.87M . Achieved all-time high total revenues of $99.6 million for Q2 2023, an 87.5% YoY increase...